MCIA Exclusive Webinar – Latest FreshLeaf Analytics Report H2 2021

MCIA is excited to invite you to an exclusive webinar hosted by FreshLeaf Analytics and AJD Media to present the H2 2021 FreshLeaf Analytics Market Report.

This report will be the 7th major publication from FreshLeaf, who has been covering the Australian medical cannabis industry since 2017, and is the leading source of information, data and insight on the sector.

Continue reading “MCIA Exclusive Webinar – Latest FreshLeaf Analytics Report H2 2021”

Meeting Your Obligations – Supplying Medicinal Cannabis in Australia Workshop

Registration is now open for the TGA ‘Meeting Your Obligations – Supplying medicinal cannabis in Australia’ Workshop. MCIA has worked with TGA to deliver this workshop to assist members and others in the industry understand their obligations and specifically assist to understand the requirements for S3 over-the-counter (OTC) product registration requirements.

Continue reading “Meeting Your Obligations – Supplying Medicinal Cannabis in Australia Workshop”

MCIA welcomes decision for down scheduled CBD with increased maximum dose of 150mg/day

Medicinal Cannabis Industry Australia (MCIA) welcomes the Therapeutic Goods Administration (TGA) announcement of its final decision regarding down-scheduling of low-dose CBD, including the significant change to the maximum dose which has been increased to 150mg/day.

MCIA had recommended changes to the interim decision, and in particular the low daily dose, to ensure that there is an effective pathway for S3 CBD products. A report commissioned by MCIA supported a higher dose based on safety and efficacy, and hence, ability to meet the evidentiary requirements for the proposed registration pathway. MCIA is pleased that TGA’s further consideration of this information, along with other public submissions, and the advice of the Joint Committee of the Advisory Committees for Medicines Scheduling and Chemicals Scheduling at its November 2020 meeting, has led to a lifting of the daily dose.

Continue reading “MCIA welcomes decision for down scheduled CBD with increased maximum dose of 150mg/day”

ACannabis Evolve 2021 – Unlocking the Potential of Medicinal Cannabis

In launching ACannabis we noted that the medicinal cannabis industry is rapidly evolving, with many voices in the conversation. ACannabis is about harnessing the collective talent, knowledge and expertise that is critical to seize the opportunities in this exciting new industry which is providing an important new medicine for patients.

Read more on the ACannabis website or Register for ACannabis EVOLVE 2021 now

Continue reading “ACannabis Evolve 2021 – Unlocking the Potential of Medicinal Cannabis”

Medicinal cannabis champion to chair new Advisory Council

Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome Dr Richard Di Natale as the inaugural chair of the newly established Medicinal Cannabis Health Advisory Council.

“Richard has been a great champion of medicinal cannabis access for patients and will provide invaluable guidance as chair of this unique and important Advisory Council” said Peter Crock Chair of MCIA.

Continue reading “Medicinal cannabis champion to chair new Advisory Council”

MCIA pursues better patient access for down scheduled CBD

In responding to the Therapeutic Goods Administration’s (TGA) interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines at appropriate dosage levels, Medicinal Cannabis Industry Australia (MCIA) has recommended further change to the proposed scheduling to ensure that there is an effective pathway for S3 CBD products.

Medicinal cannabis has an important role to play in improving health outcomes. MCIA supports down- scheduling of CBD to S3, which has the potential to provide patients with improved access to a safe low dose cannabis product for medical use.

Continue reading “MCIA pursues better patient access for down scheduled CBD”

MCIA welcomes TGA interim decision to down schedule CBD

Medicinal Cannabis Industry Australia has welcomed the interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines.

In the interim decision released today, the Therapeutic Goods Administration (TGA) has supported the down scheduling of CBD to allow greater patient access through enabling registered low-dose CBD products to be available as a Schedule 3 medicine.

Continue reading “MCIA welcomes TGA interim decision to down schedule CBD”

MCIA welcomes new Parliamentary Friends of Medicinal Cannabis Group

Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome the establishment of a Parliamentary Friends of Medicinal Cannabis Group in the Federal Parliament.

The group will provide a non-partisan forum for Members and Senators to meet with representatives of the Australian medicinal cannabis industry, medical experts and patient advocates to raise awareness of the applications of medicinal cannabis to Parliamentarians and within the broader community.

Continue reading “MCIA welcomes new Parliamentary Friends of Medicinal Cannabis Group”

Medicinal Cannabis Industry Australia (MCIA) and Medical Cannabis Council (MCC) collaborate to form a unified voice for the Australian medicinal cannabis industry

MCIA and MCC are pleased to announce that they have entered a collaboration arrangement to create a unified voice for the Australian medicinal cannabis industry.

The Australian medicinal cannabis industry has an important role to play in improving health outcomes for Australian patients. Australia is well placed to lead the world with quality medicinal cannabis, deliver next generation patient well-being, and develop a new export industry.

Continue reading “Medicinal Cannabis Industry Australia (MCIA) and Medical Cannabis Council (MCC) collaborate to form a unified voice for the Australian medicinal cannabis industry”